AZD2265 (FPI-2265) Clinical Trials (2026): 1 Studies for Metastatic Prostate Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 AZD2265 (FPI-2265) clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Metastatic Prostate Cancer) and 152 total planned enrollment. 1 AZD2265 (FPI-2265) clinical trial is actively recruiting at 2 U.S. sites across 2 states. Most recent activity: NCT07590934 (Sep 2029).
Where to Participate: All AZD2265 (FPI-2265) Trial Sites in the U.S. (2 sites across 2 states)
Every actively recruiting AZD2265 (FPI-2265)trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | Research Site | South Pasadena91030 | NCT07590934 | Map |
| FL | Research Site | Miami33165 | NCT07590934 | Map |
AZD2265 (FPI-2265) clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1/P2 | 1 | 1 |
Recruiting AZD2265 (FPI-2265) clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07590934 | PROSPECTORPhase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer | P1/P2 | Metastatic Prostate Cancer | 152 | Jun 2026 |
All AZD2265 (FPI-2265) trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07590934 | PROSPECTOR | Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer | P1/P2 | recruiting | 152 | AstraZeneca | Jun 2026 |
AZD2265 (FPI-2265) clinical trials: frequently asked questions
- How many AZD2265 (FPI-2265) clinical trials are there?
- 1 AZD2265 (FPI-2265) clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are AZD2265 (FPI-2265) clinical trials recruiting in 2026?
- Yes — 1 AZD2265 (FPI-2265) trial is actively recruiting in 2026, with 2 U.S. sites across 2 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is AZD2265 (FPI-2265) being studied for?
- AZD2265 (FPI-2265) is being studied for Metastatic Prostate Cancer. The trials are grouped by indication on this page.
- Who sponsors AZD2265 (FPI-2265) clinical trials?
- The lead sponsor across the most AZD2265 (FPI-2265) trials is AstraZeneca. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming AZD2265 (FPI-2265)as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: